CSL – 250% Gain

Posted on | by Leon Hinde

CSL has now shifted to sell conditions after being in our model portfolios since May 2015. With dividends, the stock has increased by 250%.

CSL has raised its full year profit guidance to between 3% – 8%, despite warnings of higher plasma costs. The lower end of guidance had previously been zero.

Full-year FY21 is now expected to be between $2.2bn and $2.26bn. We continue to see reliable earnings growth for CSL, however, the 40x multiple may prove to be too rich in the short-term.

CSL – Buy

Posted on | by Leon Hinde

CSL is under Algo Engine buy conditions and is a current holding in our ASX 100 model portfolio.

CSL & the Australian Government signed a Heads of Agreement to supply 51mn doses of the University of Queensland’s COVID-19 vaccine.

CSL & AstraZeneca also signed a Heads of Agreement for manufacture & distribution of 30mn doses of AZN’s COVID-19 vaccine (AZD1222).

We expect EPS to increase by 8 – 10% in FY21 and FY22. This supports a forward dividend yield of 1.1%.

Buy CSL within the $265 – $280 support range.

CSL – Buy

Posted on | by Leon Hinde

CSL is under Algo Engine buy conditions and remains one of the best-performing stocks in our ASX model portfolios.

The technical indicators show the recent higher low formation with support at $270.

CSL: Still A Blue Chip Stock

Posted on | by Leon Hinde

CSL is one of the best performing stocks within the ASX20, ASX50 and ASX100 model portfolios.

Since being added in May 2015 the share price is up 113% including dividends.

The recent retracement in the share price provides another opportunity for investors to add CSL to their portfolios.

CSL

 

Buy Healthcare Names: CSL, RMD & SHL

Posted on | by Leon Hinde

Our Algo Engine has triggered buy signals in Sonic Healthcare, Resmed and CSL over the past few trading sessions.

RMD has experienced its first sell-off since rallying from $10 last year to $16 only a few weeks ago.

The ALGO engine is now flagging the new “higher low” at $14 and we suggest buying a 1/2 size allocation here and then waiting to see if we get another ALGO signal to add to the position.

CSL provides good long-term fundamentals. The PE is still expensive, however, 10 – 20% EPS growth is attractive! Accumulate at $180

SHL looks to be good value at $23. We see resistance is $25, so look to sell call options to enhance the return. 

Chart: RMD

Chart: CSL

Chart: SHL

 

 

Quality On Sale – LLC, ASX, CSL & ALL (Video Link)

Posted on | by Leon Hinde

Lendlease, ASX, CSL and Aristocrat are names that we covered in Monday’s Opportunities in Review webinar.

Again, we draw your attention to these high quality businesses that have seen a recent correction in their share price.

We believe these names are close to finding support and should be the focus of establishing entry conditions. Watch the short-term momentum indicators for a reversal higher.

Click below to watch the short two minute video

 

 

CSL Shares Firm On Stronger Guidance

Posted on | by Todd | Leave a Comment on CSL Shares Firm On Stronger Guidance

Shares of CSL are 1% higher at $185.00 in early trade as the company announced stronger profit guidance for FY 2018.

The updated guidance has been lifted from the previous USD 1.55 to 1.6 billion range to  a USD 1.68 to 1.710 billion target.

Better than expected sales of several of their cornerstone pharmaceutical brands have supported this profit upgrade.

Despite trading near all-time highs, recent research notes have raised their medium-term price target to $190.00.

CSL is the best performing stock in our ASX Top 20 portfolio. It was first placed in the model on January 5th, 2015 at $90.00 and has gained over 105% since then.

CSL Limited